Palatin Technologies: Review of Phase 3 PL9643 Data for Dry Eye Disease
About The Event
Join us for a virtual KOL event with Palatin Technologies, featuring Bruce C. Stouch, PhD (Philadelphia College of Osteopathic Medicine) and George Ousler (Senior Vice President of Anterior Segment, Ora) who will present data from the PL9643 Phase 3 MELODY-1 trial analysis of the Lead-In population which was presented at ARVO prior to this event.
Michael B. Raizman, MD (Chief Medical Officer, Palatin Technologies) will discuss the unmet medical need and current treatment landscape for patients suffering from dry eye disease (DED) and Palatin’s potential treatment solution with its PL9643 topical eye drops.
A live question and answer session will follow the formal presentations.